#USA #Houston #Kidney Care #DaVita #ASN Kidney Week

DaVita's 25 Years of Innovation in Kidney Care Research

DaVita, a pioneering entity in kidney care, recently marked a significant milestone—25 years of innovations in clinical research and treatment. The celebration unfolded at the American Society of Nephrology's (ASN) Kidney Week 2025, held from November 5-9 in Houston, Texas. During this premier event, DaVita unveiled six new studies, highlighting its commitment to advancing treatments for kidney disease, prioritizing patient outcomes, and driving community focus.

A Commitment to Innovation

For more than two decades, DaVita has led numerous advancements that reflect its keen dedication to healthcare. With this year's research presentations, the organization aims to outline the progress made in various aspects of kidney care, including dialysis treatments, transplant access, and end-of-life considerations. Steven Brunelli, MD, Vice President of Research at DaVita, stated, "Kidney Week isn't just a conference — it's a catalyst. This year's data challenges conventional thinking and pushes the boundaries of what kidney care can be."

The studies introduced offer innovative strategies in addressing end-stage kidney disease (ESKD). An essential oral presentation, delivered by Dr. Brunelli, titled "GLP-1 Receptor Agonist Use Associated with Improvement in Hospitalization Rates in Patients with ESKD," explored how GLP-1 receptor agonists could dramatically reduce hospitalization rates among patients suffering from ESKD. This groundbreaking research represents real-world perspectives by integrating input from independent medical directors.

Key Research Insights

The following key studies were showcased at ASN Kidney Week 2025:
1. Associations of Comorbid Conditions with Outcomes in Patients Initiating Home Dialysis (Authors: Eric Weinhandl and others) - This research outlines patient outcomes concerning various comorbidities during the transition to home dialysis.
2. Positive Clinical Outcomes for In-Center Nocturnal Patients Observed in Certain Subgroups (Authors: Claire Ryan and others) - This study identified positive clinical outcomes for specific subgroups of patients undergoing nocturnal dialysis.
3. Referred Female Patients on Dialysis Are Equally Likely to Receive a Kidney Transplant (Authors: Adam G. Walker and others) - The findings challenge disparities in transplant access for female patients.
4. Dialysis Facility Staff Support is Crucial During Transplant Evaluation Process (Authors: Humberto Gonzalez-Rodriguez and others) - This study emphasizes the vital role of facility staff in assisting patients through the transplant evaluation.
5. Health Care Use at End of Life Among Patients with ESKD (Authors: Eric Weinhandl and others) - This study investigates healthcare trends and preferences among patients near the end of life.

Addressing Middle-Molecule Clearance

An exciting development highlighted by DaVita is its commitment to exploring middle-molecule clearance, an area crucial for enhancing dialysis treatment effectiveness. While conventional treatments efficiently eliminate smaller molecules, larger ones associated with chronic inflammation are often overlooked. DaVita is actively investigating innovative technologies aimed at improving patient outcomes. Chief Medical Officer, Dr. Jeff Giullian, affirmed, "As we mark 25 years of advancing kidney care, our focus is sharper than ever. We’re not just focused on extending life — we’re working to enhance the quality of every moment for the patients we serve.”

Engage with DaVita

Attendees of ASN Kidney Week are encouraged to visit DaVita at booth #702 within the George R. Brown Convention Center to engage with representatives and delve deeper into this year’s presentations and resources on middle-molecule clearance. With its longstanding commitment to improving kidney care, DaVita continues to redefine quality standards across the healthcare landscape.

For further details regarding innovative practices and insights into kidney care, visit DaVita.com/TreatmentInnovation. As they celebrate a quarter-century of dedication, DaVita stands at the forefront of transforming kidney health—prioritizing not just patient survival but their profound quality of life.